Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Utah.
Press releases published on August 25, 2025
Husband Material Ministries Announces New Book by Drew Boa: "Outgrow Porn: Find Lasting Freedom Without Fighting an Exhausting Battle—A Man's Guide to Healing"
GlobeNewswire
·
August 25, 2025
Colorado Springs, CO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Husband Material Ministries, a leading nonprofit organization dedicated to helping men find lasting freedom from pornography, is proud to announce the release of a groundbreaking new book by its …
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
GlobeNewswire
·
August 25, 2025
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced …
IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics
GlobeNewswire
·
August 25, 2025
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Empowered Patient Podcast with Karen Jagoda recently featured Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) (Nasdaq: IMDX), in an episode on “Democratizing Molecular …
The Sequoia Project Announces Detailed Agenda of Virtual Data Usability Workshop, Co-Sponsored by AHIMA
GlobeNewswire
·
August 25, 2025
VIENNA, Va., Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Sequoia Project, a non-profit and trusted advocate for nationwide health IT interoperability, in partnership with the American Health Information Management Association (AHIMA), is releasing the full …
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
GlobeNewswire
·
August 25, 2025
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan – Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may …
Muscular Dystrophy Association Launches #MDAstrong Campaign in September During Historic 75th Anniversary, Kicking Off on Labor Day Weekend
GlobeNewswire
·
August 25, 2025
New York, Aug. 25, 2025 (GLOBE NEWSWIRE) -- This September, the Muscular Dystrophy Association (MDA) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its 75th anniversary. The campaign reframes what it means to …
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
GlobeNewswire
·
August 25, 2025
HOUSTON, TX, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on September 9, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin’s …
Global Suppositories Market to Surpass USD 2.05 Billion by 2030 | MarketsandMarkets™
GlobeNewswire
·
August 25, 2025
Delray Beach, FL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The global suppositories market, valued at US$1.56 billion in 2024, stood at US$1.63 billion in 2025 and is projected to advance at a resilient CAGR of 4.7% from 2025 to 2030, culminating in a forecasted …
Global Veterinary Diagnostics Market Set to Reach USD 5.36 Billion by 2030 | MarketsandMarkets™
GlobeNewswire
·
August 25, 2025
Delray Beach, FL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The global veterinary diagnostics market, valued at US$3.42 billion in 2024, stood at US$3.68 billion in 2025 and is projected to advance at a resilient CAGR of 7.8% from 2025 to 2030, culminating in a …
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
GlobeNewswire
·
August 25, 2025
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress PRINCETON, N.J., Aug. 25, 2025 (GLOBE …
Safety Shot Secures $30 Million Strategic Investment From BONK Core Team and FalconX
GlobeNewswire
·
August 25, 2025
SCOTTSDALE, AZ, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today announced it has successfully priced a $30 million financing, anchored by a consortium of strategic investors including FalconX, the …
Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
GlobeNewswire
·
August 25, 2025
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More than 50 million people affected by acne in US each year, …
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
GlobeNewswire
·
August 25, 2025
DENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage …
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
GlobeNewswire
·
August 25, 2025
DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29th-September 1st, in Madrid, Spain, where new …
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
GlobeNewswire
·
August 25, 2025
JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior …
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
August 25, 2025
AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous …
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
GlobeNewswire
·
August 25, 2025
STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at PAINWeek 2025, taking place in Las Vegas, NV …
Avalyn to Participate in Multiple Upcoming Investor Conferences in September
GlobeNewswire
·
August 25, 2025
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced that management …
Ardelyx to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 25, 2025
WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
GlobeNewswire
·
August 25, 2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved …